Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 21.45% is 104% above its 5-year average of -480.22%, near the high end of its 5-year range (-3214.02%–243.61%).
2.88% above its 12-month average of 20.85%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 243.61%.
EBITDA MARGIN
21.45%
EBITDA MARGIN AVG TTM
20.85%
EBITDA MARGIN AVG 3Y
-217.88%
EBITDA MARGIN AVG 5Y
-480.22%
EBITDA MARGIN AVG 10Y
-233.85%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+2.88%
CURRENT VS 3Y AVG
+109.84%
CURRENT VS 5Y AVG
+104.47%
CURRENT VS 10Y AVG
+109.17%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
AnaptysBio, Inc.
Market Cap
$1.44B
EBITDA Margin
21.45%
TTM Avg
20.85%
3Y Avg
-217.88%
5Y Avg
-480.22%
Market Cap
$1.44B
EBITDA Margin
-74.29%
TTM Avg
-81.81%
3Y Avg
-115.58%
5Y Avg
-114.07%
Market Cap
$1.42B
EBITDA Margin
6.32%
TTM Avg
6.34%
3Y Avg
5.49%
5Y Avg
5.03%
Market Cap
$1.46B
EBITDA Margin
3.56%
TTM Avg
3.76%
3Y Avg
3.79%
5Y Avg
3.46%
Market Cap
$1.41B
EBITDA Margin
-10195.54%
TTM Avg
-87388.52%
3Y Avg
-48181.08%
5Y Avg
-32386.50%
Market Cap
$1.46B
EBITDA Margin
36.35%
TTM Avg
36.35%
3Y Avg
36.35%
5Y Avg
36.35%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AnaptysBio, Inc. (ANAB) | $1.44B | 21.45% | 20.85% | -217.88% | -480.22% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | -74.29% | -81.81% | -115.58% | -114.07% |
| The Pennant Group, Inc. (PNTG)vs › | $1.42B | 6.32% | 6.34% | 5.49% | 5.03% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 3.56% | 3.76% | 3.79% | 3.46% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.41B | -10195.54% | -87388.52% | -48181.08% | -32386.50% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | 36.35% | 36.35% | 36.35% | 36.35% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.48B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.48B | 18.52% | 17.87% | 16.34% | 15.57% |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.49B | N/A | N/A | N/A | N/A |
Gross Margin
99.0%
EBITDA Margin
21.4%
Operating Margin
20.4%
Net Margin
82.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 243.61% |
| 2026-03-31 | -133.15% |
| 2025-12-31 | 62.36% |
| 2025-09-30 | 46.27% |
| 2025-06-30 | -114.85% |
| 2025-03-31 | -96.98% |
| 2024-12-31 | -21.04% |
| 2024-09-30 | -73.83% |
| 2024-06-30 | -362.10% |
| 2024-03-31 | -579.41% |
| 2023-12-31 | -466.07% |
| 2023-09-30 | -1119.35% |
| 2023-06-30 | -1143.24% |
| 2023-03-31 | -3188.36% |
| 2022-12-31 | -372.61% |
| 2022-09-30 | -2246.56% |
| 2022-06-30 | -2239.14% |
| 2022-03-31 | -3214.02% |
| 2021-12-31 | -3043.72% |
| 2021-09-30 | -29.17% |
| 2021-06-30 | 1.26% |
| 2021-03-31 | -162.14% |
| 2020-12-31 | 55.82% |
| 2020-03-31 | -67.42% |
| 2019-12-31 | -737.27% |
| 2019-06-30 | -532.66% |
| 2018-09-30 | -335.92% |
| 2017-12-31 | -236.80% |
| 2017-06-30 | -35.77% |
| 2016-12-31 | -113.14% |
| 2016-09-30 | -31.64% |
| 2016-06-30 | 41.42% |
| 2016-03-31 | -22.24% |
| 2015-12-31 | -87.15% |
| 2015-09-30 | -13.77% |
| 2015-06-30 | 14.03% |
| 2015-03-31 | 10.37% |
| 2014-12-31 | 16.22% |
| 2014-09-30 | 57.69% |
| 2014-06-30 | 35.25% |
| 2014-03-31 | -25.44% |
